Invesco Biotechnology & Genome ETF
PBE
108 hedge funds and large institutions have $88.2M invested in Invesco Biotechnology & Genome ETF in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 27 reducing their positions, and 7 closing their positions.
200% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 7
29% more capital invested
Capital invested by funds: $68.4M → $88.2M (+$19.8M)
11% more funds holding
Funds holding: 97 → 108 (+11)
3.22% more ownership
Funds ownership: 30.86% → 34.08% (+3.2%)
4% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 27
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$2.73M |
| 2 |
QAM
Q3 Asset Management
Birmingham,
Michigan
|
+$1.35M |
| 3 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$1.32M |
| 4 |
Two Sigma Investments
New York
|
+$696K |
| 5 |
LPL Financial
San Diego,
California
|
+$357K |
Top Sellers
PBE Hedge Fund Activity: Q4 2025 in Review
108 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2025, worth a combined $88.2M — up 29% from $68.4M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PBE positions and 7 closed out — a net gain of 14 holders — while 26 added to existing stakes and 27 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.73M. The largest seller was UBS Group, cutting an estimated $361K.
- 108 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2025, up from 97 in Q3 2025.
- Funds reported $88.2M of Invesco Biotechnology & Genome ETF stock for Q4 2025, up 29% quarter-over-quarter.
- 21 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2025 and 7 closed out, a net change of +14 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q4 2025 was Morgan Stanley, an estimated $2.73M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q4 2025 was UBS Group, an estimated $361K sold.
Based on aggregated 13F filings for Q4 2025.